In the news release, Clinical Results Demonstrating the Performance of Biocept's Target Selector Platform to be Presented at the 2016 European Society of Medical Oncology Annual Congress, issued 29-Sep-2016 by Biocept, Inc. over PR Newswire, we are advised by the company that the first paragraph,
SAN DIEGO , Sept. 23, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that Lyle Arnold , Ph.D., Chief
SAN DIEGO , Aug. 30, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces a preferred provider agreement with
Presentation to focus on identifying medically actionable biomarkers in cancer patients using liquid biopsy to analyze both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)
Test growth and improvements in billing and collections drive more than an 8-fold increase in revenues year-over-yearConference call begins at 11:00 a.m. Eastern time today
SAN DIEGO , July 27, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the appointment of Timothy C. Kennedy as Chief Financial Officer and Senior Vice President
SAN DIEGO , July 25, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces that it will release financial results for the three and six months ended June 30, 2016
